| Jun 25 |
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
|
| Jun 21 |
ABVC Biopharma files to sell 1M shares of common stock for holders
|
| Jun 12 |
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
|
| May 24 |
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
|
| May 22 |
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
|
| May 15 |
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
|
| May 9 |
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
|
| Apr 18 |
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
|
| Apr 17 |
ABVC BioPharma executes licensing agreement with OncoX
|
| Apr 17 |
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
|
